JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $60
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $92 to $60.
Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $50
Morgan Stanley analyst Vikram Purohit maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and lowers the price target from $53 to $50.
Guggenheim Maintains Buy on Sage Therapeutics, Lowers Price Target to $48
Guggenheim analyst Yatin Suneja maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $55 to $48.
HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $50
HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $55 to $50.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Loop Capital Initiates Coverage On Sage Therapeutics with Hold Rating, Announces Price Target of $41
Loop Capital analyst Esther Hong initiates coverage on Sage Therapeutics (NASDAQ:SAGE) with a Hold rating and announces Price Target of $41.
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with…
Sage Therapeutics And Biogen Present New Analyses At Psych Congress Further Evaluating The Efficacy And Safety Of Zuranolone
Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical
Sage Therapeutics: Q2 Earnings Insights
Sage Therapeutics (NASDAQ:SAGE) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.
Sage Therapeutics Q2 EPS $(2.13) Beats $(2.15) Estimate, Sales $1.50M Miss $1.76M Estimate
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.13) per share which beat the analyst consensus estimate of $(2.15) by 0.93 percent. This is a 16.39 percent decrease over losses of $(1.83) per share from